|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
US8651113B2
(en)
*
|
2003-06-18 |
2014-02-18 |
Swr&D Inc. |
Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
|
|
WO2005016349A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Methods of inhibiting leukocyte accumulation
|
|
US20050043239A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Jason Douangpanya |
Methods of inhibiting immune responses stimulated by an endogenous factor
|
|
EP3556866B1
(en)
|
2004-03-02 |
2021-04-07 |
The Johns Hopkins University |
Mutations of the pik3ca gene in human cancers
|
|
ES2605792T3
(es)
|
2004-05-13 |
2017-03-16 |
Icos Corporation |
Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
|
|
CA2567883A1
(en)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
|
|
AU2006214190A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
|
WO2007086943A2
(en)
*
|
2005-09-01 |
2007-08-02 |
Beth Israel Deaconess Medical Center |
Wortmannin conjugates and uses thereof
|
|
WO2007035395A2
(en)
*
|
2005-09-16 |
2007-03-29 |
Virginia Commonwealth University Intellectual Property Foundation |
Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors
|
|
JP2009519234A
(ja)
*
|
2005-12-01 |
2009-05-14 |
ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン |
癌および感染性疾患の処置に関する組成物および方法
|
|
TWI426905B
(zh)
*
|
2006-02-09 |
2014-02-21 |
Enzon Pharmaceuticals Inc |
用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
|
|
US8329683B2
(en)
*
|
2006-06-02 |
2012-12-11 |
Nexgenix Pharmaceuticals, Llc |
Treatment of neurofibromatosis with radicicol and its derivatives
|
|
WO2007143630A2
(en)
*
|
2006-06-02 |
2007-12-13 |
Nexgenix Pharmaceuticals |
Treatment of neurofibromatosis with hsp90 inhibitors
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8557807B2
(en)
*
|
2008-01-24 |
2013-10-15 |
Signal Rx Pharmaceuticals, Inc. |
Thienopyranones as kinase inhibitors
|
|
WO2009108704A1
(en)
*
|
2008-02-25 |
2009-09-03 |
Semafore Pharmaceuticals, Inc. |
O-alkylated pi-3 kinase inhibitor prodrug combination
|
|
DE102008001855A1
(de)
*
|
2008-05-19 |
2009-11-26 |
Evonik Degussa Gmbh |
Zweikomponenten-Zusammensetzung zur Herstellung von flexiblen Polyurethan-Gelcoats
|
|
EP2303288A4
(en)
|
2008-05-22 |
2015-04-22 |
Univ Ramot |
CONJUGATES OF A POLYMER, BISPHOSPHONATE AND ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF DISEASES RELATING TO BONES
|
|
US8524691B2
(en)
|
2008-08-13 |
2013-09-03 |
The Medicines Company |
Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
SG10201703911XA
(en)
|
2008-11-13 |
2017-06-29 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
US8864627B2
(en)
|
2009-03-17 |
2014-10-21 |
Woodway Usa, Inc. |
Power generating manually operated treadmill
|
|
CN102439012A
(zh)
|
2009-03-24 |
2012-05-02 |
吉里德卡利斯托加公司 |
2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
|
|
CA2759724A1
(en)
|
2009-04-20 |
2010-10-28 |
Calistoga Pharmaceuticals, Inc. |
Methods of treatment for solid tumors
|
|
HUE033442T2
(en)
|
2009-06-25 |
2017-11-28 |
Alkermes Pharma Ireland Ltd |
Heterocyclic compounds for the treatment of neurological and psychological disorders
|
|
WO2010151711A1
(en)
|
2009-06-25 |
2010-12-29 |
Alkermes, Inc. |
Prodrugs of nh-acidic compounds
|
|
US8691829B2
(en)
|
2009-07-21 |
2014-04-08 |
Gilead Calistoga Llc |
Treatment of liver disorders with PI3K inhibitors
|
|
US8314934B2
(en)
|
2009-09-01 |
2012-11-20 |
Alltech Associates, Inc. |
Methods and apparatus for analyzing samples and collecting sample fractions
|
|
ES2651682T3
(es)
*
|
2009-11-05 |
2018-01-29 |
Rhizen Pharmaceuticals S.A. |
Moduladores de cinasa novedosos
|
|
US8592427B2
(en)
|
2010-06-24 |
2013-11-26 |
Alkermes Pharma Ireland Limited |
Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
|
|
KR101591153B1
(ko)
|
2010-12-20 |
2016-02-02 |
그렌마크 파머수티칼스 에스. 아. |
Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
|
|
CN112451477B
(zh)
|
2011-03-18 |
2022-12-30 |
奥克梅斯制药爱尔兰有限公司 |
包含脱水山梨糖醇酯的药物组合物
|
|
JP2014514300A
(ja)
*
|
2011-04-08 |
2014-06-19 |
スファエラ ファーマ ピーティーイー リミテッド |
置換メチルホルミル試薬並びに化合物の物理化学的性質及び／又は薬物動態学的性質を改質するためのそれらの使用方法
|
|
CN103930135A
(zh)
*
|
2011-08-31 |
2014-07-16 |
马林克罗特有限公司 |
使用h-膦酸酯的纳米颗粒peg修饰
|
|
NZ722096A
(en)
|
2011-12-15 |
2016-11-25 |
Alkermes Pharma Ireland Ltd |
Prodrugs of secondary amine compounds
|
|
BRPI1107182B1
(pt)
*
|
2011-12-29 |
2022-03-08 |
Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig |
Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
|
|
IN2014MN01819A
(enExample)
|
2012-03-05 |
2015-07-03 |
Univ Ramot |
|
|
CN106146506A
(zh)
|
2012-03-05 |
2016-11-23 |
吉利德卡利斯托加公司 |
(s)‑2‑(1‑(9h‑嘌呤‑6‑基氨基)丙基)‑5‑氟‑3‑苯基喹唑啉‑4(3h)‑酮的多晶型物
|
|
AU2013235519C1
(en)
|
2012-03-19 |
2018-04-26 |
Alkermes Pharma Ireland Limited |
Pharmaaceutical compositions comprising fatty acid esters
|
|
EP2827866B1
(en)
|
2012-03-19 |
2023-05-03 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising benzyl alcohol
|
|
CA2867123C
(en)
|
2012-03-19 |
2021-02-16 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
|
|
NZ631345A
(en)
|
2012-09-19 |
2017-06-30 |
Alkermes Pharma Ireland Ltd |
Pharmaceutical compositions having improved storage stability
|
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
|
US10072018B2
(en)
|
2013-04-17 |
2018-09-11 |
Biopharma Works |
Compounds for treatment of pain
|
|
US9487531B2
(en)
|
2013-04-17 |
2016-11-08 |
BioPharma Works LLC |
Compounds for treatment of pain
|
|
EP3083630B1
(en)
|
2013-12-20 |
2019-08-21 |
Gilead Calistoga LLC |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
|
WO2015095605A1
(en)
|
2013-12-20 |
2015-06-25 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
|
ES2921874T3
(es)
|
2014-02-28 |
2022-09-01 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
|
WO2015140257A1
(en)
|
2014-03-19 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for inducing human cholangiocyte differentiation
|
|
EP3119399A4
(en)
|
2014-03-20 |
2017-09-27 |
Alkermes Pharma Ireland Limited |
Aripiprazole formulations having increased injection speeds
|
|
AU2015274696B2
(en)
|
2014-06-13 |
2018-09-27 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
|
WO2016065142A2
(en)
|
2014-10-22 |
2016-04-28 |
The Johns Hopkins University |
New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
|
|
RU2708459C2
(ru)
|
2014-10-29 |
2019-12-09 |
БайсиклРД Лимитед |
Бициклические пептидные лиганды, специфичные для мт1-ммр
|
|
EP3262049B1
(en)
|
2015-02-27 |
2022-07-20 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
MX377208B
(es)
*
|
2015-07-07 |
2025-03-07 |
Five Eleven Pharma Inc |
Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
|
|
EP3344624B8
(en)
|
2015-09-02 |
2023-11-29 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
JP7118888B2
(ja)
|
2015-09-08 |
2022-08-16 |
モナッシュ ユニバーシティ |
リンパ指向性プロドラッグ
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
WO2017062504A1
(en)
|
2015-10-06 |
2017-04-13 |
Woodway Usa, Inc. |
Manual treadmill and methods of operating the same
|
|
LT3364958T
(lt)
|
2015-10-23 |
2023-06-12 |
Navitor Pharmaceuticals, Inc. |
Sestrin-gator2 sąveikos moduliatoriai ir jų panaudojimas
|
|
WO2017086397A1
(ja)
*
|
2015-11-17 |
2017-05-26 |
日産化学工業株式会社 |
オリゴヌクレオチドの製造方法
|
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
|
PL3426244T3
(pl)
|
2016-03-09 |
2023-09-25 |
Raze Therapeutics, Inc. |
Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
|
|
HUE055197T2
(hu)
|
2016-03-09 |
2021-11-29 |
Raze Therapeutics Inc |
3-Foszfoglicerát-dehidrogenáz inhibitorok és alkalmazásuk
|
|
WO2017162536A1
(en)
|
2016-03-21 |
2017-09-28 |
H. Lundbeck A/S |
Vortioxetine prodrugs
|
|
WO2017175022A1
(en)
|
2016-04-07 |
2017-10-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for inhibiting mast cell degranulation
|
|
EP3440112A4
(en)
|
2016-04-08 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
METHOD FOR THE TREATMENT OF CANCER
|
|
CN109641838A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
CA3027495A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
US10238911B2
(en)
|
2016-07-01 |
2019-03-26 |
Woodway Usa, Inc. |
Motorized treadmill with motor braking mechanism and methods of operating same
|
|
US10072032B2
(en)
*
|
2016-09-19 |
2018-09-11 |
Afton Chemical Corporation |
AminoBisPhosphonate antiwear additives
|
|
CA3039202A1
(en)
|
2016-10-14 |
2018-04-19 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CA3040286A1
(en)
|
2016-10-21 |
2018-04-26 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
US11730819B2
(en)
|
2016-12-23 |
2023-08-22 |
Bicycletx Limited |
Peptide derivatives having novel linkage structures
|
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
JP2020506904A
(ja)
|
2017-01-27 |
2020-03-05 |
シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド |
キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
|
|
EP4338802A3
(en)
|
2017-03-08 |
2024-09-04 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
US20200138964A1
(en)
*
|
2017-04-25 |
2020-05-07 |
Seikagaku Corporation |
Tertiary amine compound or imine compound-polymer conjugate and production method therefor
|
|
CN116370448B
(zh)
|
2017-04-26 |
2026-01-13 |
纳维托制药有限公司 |
Sestrin-gator2相互作用的调节剂及其用途
|
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
PL3619196T3
(pl)
|
2017-05-04 |
2022-08-29 |
Bayer Cropscience Aktiengesellschaft |
Pochodne 2-{[2-(fenyloksymetylo)pirydyn-5-yl]oksy}-etanoaminy i związki pokrewne jako środki do zwalczania szkodników np. do ochrony upraw
|
|
CN108929329B
(zh)
*
|
2017-05-24 |
2020-12-11 |
中国医学科学院药物研究所 |
2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
US11046698B2
(en)
|
2017-07-28 |
2021-06-29 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
EP3661948B1
(en)
|
2017-08-04 |
2022-06-01 |
BicycleTx Limited |
Bicyclic peptide ligands specific for cd137
|
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
AU2018324037A1
(en)
|
2017-08-29 |
2020-04-16 |
Monash University |
Lymphatic system-directing lipid prodrugs
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
CA3076613A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
CN108003188A
(zh)
*
|
2017-12-25 |
2018-05-08 |
长春吉大天元化学技术股份有限公司 |
一种烷基磷酸酯类化合物的新型纯化方法
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US10988477B2
(en)
|
2018-01-29 |
2021-04-27 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
|
EP3755725A1
(en)
|
2018-02-23 |
2020-12-30 |
BicycleTX Limited |
Multimeric bicyclic peptide ligands
|
|
SG11202008067QA
(en)
|
2018-02-27 |
2020-09-29 |
Artax Biopharma Inc |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
US11273158B2
(en)
|
2018-03-05 |
2022-03-15 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
|
TWI884914B
(zh)
|
2018-04-24 |
2025-06-01 |
美商維泰克斯製藥公司 |
喋啶酮化合物及其用途
|
|
PL4043460T3
(pl)
|
2018-04-24 |
2024-10-28 |
Merck Patent Gmbh |
Związki przeciwproliferacyjne i ich zastosowania
|
|
RS65761B1
(sr)
|
2018-06-15 |
2024-08-30 |
Janssen Pharmaceutica Nv |
Analozi rapamicina i njihova upotreba
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US20210300939A1
(en)
|
2018-07-23 |
2021-09-30 |
Signalrx Pharmaceuticals, Inc. |
Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
US20220257781A1
(en)
*
|
2018-09-06 |
2022-08-18 |
Seikagaku Corporation |
Polymer conjugate bonded to tertiary amine compound or imine compound and production method therefor
|
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
JP2022512779A
(ja)
|
2018-10-23 |
2022-02-07 |
バイスクルテクス・リミテッド |
二環式ペプチドリガンドおよびその使用
|
|
CN113164414A
(zh)
|
2018-10-24 |
2021-07-23 |
纳维托制药有限公司 |
多晶型化合物和其用途
|
|
US11053241B2
(en)
|
2018-11-30 |
2021-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
KR20250167680A
(ko)
|
2018-11-30 |
2025-12-01 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
バイスクルテクス・リミテッド |
Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
|
|
CN113348021B
(zh)
|
2019-01-23 |
2025-07-11 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
USD930089S1
(en)
|
2019-03-12 |
2021-09-07 |
Woodway Usa, Inc. |
Treadmill
|
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
|
TWI875749B
(zh)
|
2019-04-05 |
2025-03-11 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
|
KR20220034739A
(ko)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
TWI862640B
(zh)
|
2019-07-30 |
2024-11-21 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
AU2020345962A1
(en)
|
2019-09-11 |
2022-03-31 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
TWI870497B
(zh)
|
2019-11-01 |
2025-01-21 |
美商奈維特製藥公司 |
使用mtorc1調節劑的治療方法
|
|
KR20220128345A
(ko)
|
2019-12-05 |
2022-09-20 |
아나쿠리아 테라퓨틱스, 인코포레이티드 |
라파마이신 유사체 및 이의 용도
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2020407200A1
(en)
|
2019-12-17 |
2022-07-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220151160A
(ko)
|
2019-12-23 |
2022-11-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Smarca 분해제 및 이의 용도
|
|
KR20220149534A
(ko)
|
2020-02-05 |
2022-11-08 |
퓨어테크 엘와이티, 아이엔씨. |
신경스테로이드의 지질 전구약물
|
|
CA3170411A1
(en)
|
2020-03-03 |
2021-09-10 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
|
EP4121043A4
(en)
|
2020-03-19 |
2024-07-24 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
EP4232425A4
(en)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1 inhibitors and uses thereof
|
|
JP2023553866A
(ja)
|
2020-12-02 |
2023-12-26 |
イケナ オンコロジー， インコーポレイテッド |
Ｔｅａｄ阻害剤、及びその使用
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
MX2023009060A
(es)
|
2021-02-02 |
2023-09-29 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
WO2022174269A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
EP4319756A4
(en)
|
2021-04-09 |
2025-02-26 |
Nimbus Clio, Inc. |
CBL-B MODULATORS AND USES THEREOF
|
|
IL307673A
(en)
|
2021-04-16 |
2023-12-01 |
Ikena Oncology Inc |
MEK inhibitors and their use
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
CN118019739A
(zh)
|
2021-08-25 |
2024-05-10 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
|
US12234231B2
(en)
|
2021-08-25 |
2025-02-25 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
AR127505A1
(es)
|
2021-10-29 |
2024-01-31 |
Kymera Therapeutics Inc |
Degradadores irak-4 y síntesis de los mismos
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Ｍｅｋ抑制劑及其用途
|
|
JP2025527248A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
|
|
IL318575A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
|
|
KR20250057801A
(ko)
|
2022-08-02 |
2025-04-29 |
리미널 바이오사이언시스 리미티드 |
아릴-트라이아졸릴 및 관련 gpr84 길항제 및 이의 용도
|
|
AR131141A1
(es)
|
2022-11-22 |
2025-02-19 |
Pic Therapeutics Inc |
Inhibidores de eif4e y usos de los mismos
|
|
CN120379669A
(zh)
|
2023-06-23 |
2025-07-25 |
凯麦拉医疗公司 |
Irak降解剂及其用途
|
|
TW202529769A
(zh)
|
2023-09-21 |
2025-08-01 |
日商武田藥品工業股份有限公司 |
Ｔｙｋ２抑制劑及其用途
|